Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106694 | 1.00 | BACE1 (0.33) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2108535 | 1.00 | BACE1 (0.33) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2106691 | 1.00 | BACE1 (0.33) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2108536 | 1.00 | BACE1 (0.33) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2106700 | 0.96 | BACE1 (0.32) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2106703 | 0.96 | BACE1 (0.32) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2109600 | 0.96 | BACE1 (0.32) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2109598 | 0.96 | BACE1 (0.32) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2106705 | 0.96 | BACE1 (0.32) | BACE1BACE2L3MBTL1ALDH1A1GAA | |
| SCHEMBL2108779 | 0.92 | BACE2 (0.33) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8158620-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885L3MBTL1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.